Uses of pharmacovigilance databases: An overview.
暂无分享,去创建一个
Christian Funck-Brentano | Kévin Bihan | Bénédicte Lebrun-Vignes | Joe-Elie Salem | C. Funck-Brentano | J. Salem | B. Lebrun-Vignes | K. Bihan
[1] Paul Beninger,et al. Pharmacovigilance: An Overview. , 2018, Clinical therapeutics.
[2] F. Badilini,et al. Complex Influence of Gonadotropins and Sex Steroid Hormones on QT Interval Duration. , 2016, The Journal of clinical endocrinology and metabolism.
[3] Richard C. Zink,et al. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance , 2018, Therapeutic innovation & regulatory science.
[4] S. Evans,et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.
[5] Effect of Date of Drug Marketing on Disproportionality Measures in Pharmacovigilance , 2009, Drug safety.
[6] A. Pariente,et al. Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases The Notoriety Bias , 2007, Drug safety.
[7] Bénédicte Lebrun-Vignes,et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis , 2018, The Lancet.
[8] T. Vial. French pharmacovigilance: Missions, organization and perspectives. , 2016, Therapie.
[9] Andrew Bate,et al. Bayesian Confidence Propagation Neural Network , 2007, Drug safety.
[10] M. Lindquist,et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions , 2002, Pharmacoepidemiology and drug safety.
[11] L. Arnaud,et al. Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase. , 2019, The Journal of allergy and clinical immunology.
[12] J. Sosman,et al. Reporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply , 2018, The Lancet.
[13] William DuMouchel,et al. Empirical bayes screening for multi-item associations , 2001, KDD '01.
[14] R. O’Neill,et al. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA’s Spontaneous Reports Database , 2002, Drug safety.
[15] T. Kajii,et al. The effect of thalidomide intake during 113 human pregnancies. , 1973, Teratology.
[16] Kristina Juhlin,et al. Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases , 2015, Drug Safety.
[17] M. Humbert,et al. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study , 2019, European Respiratory Journal.
[18] K.,et al. Hematologic Complications of Immune Checkpoint Inhibitors , 2019, The oncologist.
[19] Ismaïl Ahmed,et al. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases , 2016, Drug Safety.
[20] A. Mammen,et al. Immune Checkpoint Inhibitor-Associated Myositis. , 2018, Circulation.
[21] F. Haramburu,et al. Causality assessment in pharmacovigilance: The French method and its successive updates. , 2016, Therapie.
[22] C. Guy,et al. Is acetaminophen associated with a risk of Stevens–Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database , 2018, British journal of clinical pharmacology.
[23] D. Trégouët,et al. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women , 2018, JAMA cardiology.
[24] A history of pharmacoepidemiology. , 2019, Therapie.
[25] C. Funck-Brentano,et al. Cardiac arrhythmia considerations of hormone cancer therapies , 2019, Cardiovascular research.
[26] A. Pariente,et al. A Potential Event-Competition Bias in Safety Signal Detection: Results from a Spontaneous Reporting Research Database in France , 2013, Drug Safety.
[27] M. Lindquist. Use of Triage Strategies in the WHO Signal-Detection Process , 2007, Drug safety.
[28] M. Lapeyre-Mestre,et al. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting , 2018, Drug Safety.
[29] E. Lipson,et al. Cardiovascular toxicities associated with immune checkpoint inhibitors , 2019, Cardiovascular research.
[30] G. Niklas Norén,et al. Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank , 2014, Drug Safety.
[31] Ismaïl Ahmed,et al. Early Detection of Pharmacovigilance Signals with Automated Methods Based on False Discovery Rates , 2012, Drug Safety.
[32] B. Kuehn. FDA: Acetaminophen may trigger serious skin problems. , 2013, JAMA.
[33] L. Arnaud,et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database , 2019, Annals of the rheumatic diseases.
[34] C. Funck-Brentano,et al. Influence of steroid hormones on ventricular repolarization. , 2016, Pharmacology & therapeutics.
[35] L. Arnaud,et al. Checkpoint inhibitor-associated immune arthritis , 2018, Annals of the rheumatic diseases.
[36] D. Roden,et al. Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. , 2018, Circulation.
[37] D. Roden,et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors , 2018, Heart.
[38] Douglas B. Johnson,et al. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis. , 2019, European journal of cancer.
[39] Frantz Thiessard,et al. The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions , 2005, Pharmacoepidemiology and drug safety.
[40] D. Roden,et al. Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. , 2019, Circulation.
[41] M. Lapeyre-Mestre,et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics , 2017, British journal of clinical pharmacology.
[42] J. Faillie. Case-non-case studies: Principle, methods, bias and interpretation. , 2019, Therapie.
[43] A. Mantel‐Teeuwisse,et al. Characteristics of drugs safety signals that predict safety related product information update , 2018, Pharmacoepidemiology and drug safety.
[44] J. Lefrère,et al. Les bébés du thalidomide. , 2011, Presse medicale.
[45] B Bégaud,et al. Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France , 1985 .
[46] M. Hauben,et al. Quantitative Methods in Pharmacovigilance , 2003, Drug safety.
[47] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[48] N. Moore,et al. Pharmacovigilance - The next chapter. , 2019, Therapie.
[49] C. Funck-Brentano,et al. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. , 2019, Archives of cardiovascular diseases.
[50] Qi Jiang,et al. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights , 2018, Therapeutic innovation & regulatory science.
[51] Kenneth J Rothman,et al. The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.
[52] Douglas B. Johnson,et al. Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes , 2018, Diabetes Care.
[53] Sophie Gautier,et al. The history of pharmacovigilance. , 2016, Therapie.
[54] J. Dogné,et al. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection , 2018, Drug Safety.
[55] Marc P. Bonaca,et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.
[56] A. Mammen,et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study , 2019, Journal of Immunotherapy for Cancer.